Related Experiment Video
Updated: Jul 10, 2026

Production of Replication-Defective Retrovirus by Transient Transfection of 293T cells
Published on: December 4, 2007
An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene
Byoung Y Ryu1, Marguerite V Evans-Galea, John T Gray
1Department of Hematology, St Jude Children's Research Hospital, Memphis, TN 38105, USA.
Abstract:
Pathogenic activation of the LMO2 proto-oncogene by an oncoretroviral vector insertion in a clinical trial for X-linked severe combined immunodeficiency (X-SCID) has prompted safety concerns. We used an adeno-associated virus vector to achieve targeted insertion of a gamma-retroviral long terminal repeat (LTR) driving a GFP expression cassette with flanking loxP sites in a human T-cell line at the precise location of vector integration in one of the patients with X-SCID. The LTR-GFP cassette was inserted into the first intron of the LMO2 gene, resulting in strong activation of LMO2. Cre-mediated cassette exchange was used to replace the original LTR-GFP cassette with one flanked by insulator elements leading to a several fold reduction in LMO2 expression. The LTR-GFP cassette was also replaced with a globin gene regulatory cassette that failed to activate the LMO2 gene in lymphoid cells. A gamma-retroviral vector with 2 intact LTRs resulted in activation of the LMO2 gene when inserted into the first intron, but a self-inactivating lentiviral vector with an internal cellular promoter and flanking insulator elements did not activate the LMO2 gene. Thus, this system is useful for comparing the safety profiles of vector cassettes with various regulatory elements for their potential for proto-oncogene activation.
Insights
Gene therapy safety concerns, particularly LMO2 proto-oncogene activation in X-linked severe combined immunodeficiency (X-SCID) trials, were addressed. Researchers developed a system to compare vector safety, reducing proto-oncogene activation risks.
Area of Science:
- Gene therapy
- Oncology
- Immunology
Background:
- Clinical trials using oncoretroviral vectors for X-linked severe combined immunodeficiency (X-SCID) faced safety issues due to LMO2 proto-oncogene activation.
- This activation poses a significant risk for leukemogenesis in patients.
Purpose of the Study:
- To develop and validate a system for comparing the safety profiles of different gene therapy vector cassettes.
- To assess the potential for proto-oncogene activation by various regulatory elements within gene therapy vectors.
Main Methods:
- Adeno-associated virus (AAV) vector used for targeted insertion of a gamma-retroviral LTR-GFP cassette into the LMO2 gene in a human T-cell line.
- Cre-mediated cassette exchange employed to replace the LTR-GFP cassette with insulator-flanked or globin gene regulatory cassettes.
- Comparison of LMO2 expression levels after insertion of different vector designs, including gamma-retroviral and self-inactivating lentiviral vectors.
Main Results:
- Insertion of the LTR-GFP cassette into the LMO2 gene's first intron strongly activated LMO2 expression.
- Replacing the cassette with insulator-flanked elements reduced LMO2 expression significantly.
- A self-inactivating lentiviral vector with insulator elements did not activate LMO2, unlike a gamma-retroviral vector.
Conclusions:
- The developed system effectively compares vector cassette safety regarding proto-oncogene activation.
- Vector design, particularly the use of insulators and self-inactivating elements, is crucial for mitigating risks like LMO2 activation in gene therapy.
More Related Videos
11:50Retroviral Transduction of Helper T Cells as a Genetic Approach to Study Mechanisms Controlling their Differentiation and Function
Published on: November 4, 2016
11:28Designing, Packaging, and Delivery of High Titer CRISPR Retro and Lentiviruses via Stereotaxic Injection
Published on: May 23, 2016
Related Concept Videos
Mechanisms of Retrovirus-induced Cancers
Mechanisms of Retrovirus-induced Cancers
In-vitro Mutagenesis
Retroviruses